Target Price | $54.82 |
Price | $48.30 |
Potential |
13.50%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Guardant Health, Inc. 2026 .
The average Guardant Health, Inc. target price is $54.82.
This is
13.50%
register free of charge
$65.00
34.58%
register free of charge
$20.00
58.59%
register free of charge
|
|
A rating was issued by 26 analysts: 23 Analysts recommend Guardant Health, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of
13.50%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 739.02 | 858.04 |
31.04% | 16.10% | |
EBITDA Margin | -54.29% | -26.40% |
41.08% | 51.37% | |
Net Margin | -59.73% | -41.94% |
36.53% | 29.78% |
23 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
20 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.56 | -2.90 |
16.82% | 18.54% | |
P/E | negative | |
EV/Sales | 7.53 |
20 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Analyst Rating | Date |
---|---|
Locked
Barclays:
Locked
➜
Locked
|
Apr 10 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
Apr 10 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 26 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 06 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 24 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.